| 1.13 -0.04 (-3.42%) | 10-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.59 |
1-year : | 1.96 |
| Resists | First : | 1.36 |
Second : | 1.67 |
| Pivot price | 1.12 |
|||
| Supports | First : | 0.86 | Second : | 0.71 |
| MAs | MA(5) : | 1.17 |
MA(20) : | 1.16 |
| MA(100) : | 1.74 |
MA(250) : | 1.73 |
|
| MACD | MACD : | -0.2  |
Signal : | -0.2 |
| %K %D | K(14,3) : | 64.9 |
D(3) : | 62 |
| RSI | RSI(14): 41.1 |
|||
| 52-week | High : | 2.66 | Low : | 0.86 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ALXO ] has closed below upper band by 48.9%. Bollinger Bands are 21.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.19 - 1.2 | 1.2 - 1.2 |
| Low: | 1.07 - 1.08 | 1.08 - 1.09 |
| Close: | 1.12 - 1.13 | 1.13 - 1.14 |
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Fri, 23 Oct 2026
ALX Oncology Holdings Inc. Estimates – NASDAQ:ALXO - TradingView
Fri, 16 Oct 2026
A $0.001-per-share warrant is at the center of ALX Oncology (ALXO)'s agreed share exchange. - Stock Titan
Mon, 28 Sep 2026
A cancer drug had a 63.6% response rate in one group, but its maker won't seek a U.S. stomach-cancer approval trial - Stock Titan
Tue, 11 Aug 2026
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Thu, 06 Aug 2026
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Investing News Network
Thu, 25 Jun 2026
ALXO Forecast — Price Target — Prediction for 2027 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 138 (M) |
| Shares Float | 95 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 93.5 (%) |
| Shares Short | 5,670 (K) |
| Shares Short P.Month | 7,060 (K) |
| EPS | -1.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.99 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -40.5 % |
| Return on Equity (ttm) | -80.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -71 (M) |
| Levered Free Cash Flow | -41 (M) |
| PE Ratio | -1 |
| PEG Ratio | 0 |
| Price to Book value | 1.14 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|